Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure

American Heart Journal

Volumn 158, Issue 5, 2009, Pages 777-783

  Rogers, Robert Kevin ^a   May, Heidi T ^b   Anderson, Jeffrey L ^a,b   Muhlestein, J Brent ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; EVENT FREE SURVIVAL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIASTOLE; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 70350054637     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.09.002     Document Type: Article

References (44)

1. Ndrepepa G., Braun S., Schomig A., et al. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. Am J Cardiol 100 (2007) 575-578
2. Palmer B.R., Pilbrow A.P., Yandle T.G., et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 41 (2003) 729-736
3. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
4. Dokainish H., Zoghbi W.A., Lakkis N.M., et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 45 (2005) 1223-1226
5. Horwich T.B., Hamilton M.A., and Fonarow G.C. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47 (2006) 85-90
6. Parsonage W.A., Galbraith A.J., Koerbin G.L., et al. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 95 (2005) 883-885
7. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47 (2006) 582-586
8. Fonarow G.C., Peacock W.F., Phillips C.O., et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 1943-1950
9. Kragelund C., Gronning B., Kober L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
10. Richards M., Nicholls M.G., Espiner E.A., et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 (2006) 52-60
11. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
12. Kwan G., Isakson S.R., Beede J., et al. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol 49 (2007) 1186-1192
13. Lindahl B., Lindback J., Jernberg T., et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45 (2005) 533-541
14. Androne A.S., Hryniewicz K., Hudaihed A., et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 93 (2004) 1254-1259
15. Schnabel R., Lubos E., Rupprecht H.J., et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 47 (2006) 552-558
16. Tapanainen J.M., Lindgren K.S., Makikallio T.H., et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 43 (2004) 757-763
17. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
18. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 (2004) 1328-1333
19. Bibbins-Domingo K., Gupta R., Na B., et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
20. Shah M.R., Hasselblad V., Tasissa G., et al. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol 100 (2007) 1427-1433
21. Cappola T.P., Felker G.M., Kao W.H., et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 105 (2002) 1663-1668
22. Richards A.M., Crozier I.G., Yandle T.G., et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69 (1993) 414-417
23. Joung B., Ha J.W., Ko Y.G., et al. Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function?. Am Heart J 150 (2005) 1213-1219
24. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 (2006) 742-748
25. O'Neill J.O., Bott-Silverman C.E., McRae III A.T., et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149 (2005) 363-369
26. Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832
27. Taylor J.A., Christenson R.H., Rao K., et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 152 (2006) 1071-1076
28. Tschope C., Kasner M., Westermann D., et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005) 2277-2284
29. Murakami Y., Shimada T., Inoue S., et al. New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18 (2002) 1294-1300
30. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
31. Ndrepepa G., Braun S., Mehilli J., et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 95 (2005) 553-557
32. Taylor G.S., Muhlestein J.B., Wagner G.S., et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 136 (1998) 792-803
33. Schiller N.B., Acquatella H., Ports T.A., et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 60 (1979) 547-555
34. Omland T., Sabatine M.S., Jablonski K.A., et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 50 (2007) 205-214
35. Ndrepepa G., Braun S., Niemoller K., et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 112 (2005) 2102-2107
36. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
37. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
38. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
39. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
40. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49 (2007) 1071-1078
41. Forfia P.R., Lee M., Tunin R.S., et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49 (2007) 1079-1088
42. Ni X.P., Safai M., Rishi R., et al. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat. J Am Soc Nephrol 15 (2004) 1254-1260
43. Ni X.P., Safai M., Gardner D.G., et al. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int 59 (2001) 1264-1273
44. Charloux A., Piquard F., Doutreleau S., et al. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33 (2003) 769-778